These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 5290707)

  • 1. On the origin of the proteolytic activity responsible for the release of fibrinogen-fibrin related antigen in vitro.
    Johnson AJ; Merskey C
    Scand J Haematol Suppl; 1971; 13():87-9. PubMed ID: 5290707
    [No Abstract]   [Full Text] [Related]  

  • 2. Tanned Red Cell Hemagglutination Inhibition Immunoassay for fibrinogen-fibrin-related antigen ("fibrinolytic degradation products") in human serum.
    Merskey C; Lalezari P; Johnson AJ
    Scand J Haematol Suppl; 1971; 13():83-5. PubMed ID: 5290706
    [No Abstract]   [Full Text] [Related]  

  • 3. Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin.
    Merskey C; Johnson AJ; Lalezari P
    J Clin Invest; 1972 Apr; 51(4):903-11. PubMed ID: 5014617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin lysis by thrombin elevating levels of fibrinogen and fibrin-related antigen (FR-antigen) in human serum as shown by Auto Analyzer assay.
    Merskey C; Johnson AJ; Lalezari P
    J Clin Pathol; 1972 Jul; 25(7):623. PubMed ID: 5070262
    [No Abstract]   [Full Text] [Related]  

  • 5. Derivatives of fibrinogen and fibrin during defibrase therapy. Separation of high and low molecular weight derivatives of fibrinogen and fibrin by agarose gel filtration.
    Asbeck F; Lechler E; Martin M; van de Loo J
    Haemostasis; 1974; 3(5-6):340-7. PubMed ID: 4468232
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of fibrin(ogen) degradation products by a latex clumping method.
    Allington MJ
    Scand J Haematol Suppl; 1971; 13():115-9. PubMed ID: 5290675
    [No Abstract]   [Full Text] [Related]  

  • 7. [Blood coagulation and fibrinolysis in venous blood after prophylactic use of antifibrinolytic agents in heart surgery with the use of xtracorporeal circulation].
    Deutschinoff A; Dimitrov D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1967; 88(2):166-73. PubMed ID: 4174654
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental and clinical studies on the thrombin-like enzyme from the venom of Bothrops atrox. On the primary structure of fragment E.
    Egberg N
    Acta Physiol Scand Suppl; 1973; 400():1-47. PubMed ID: 4599946
    [No Abstract]   [Full Text] [Related]  

  • 9. Fibrinogen to fibrin transformation in umbilical cord blood and purified neonatal fibrinogen.
    Teger-Nilsson AC; Ekelund H
    Thromb Res; 1974 Nov; 5(5):601-12. PubMed ID: 4445984
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies.
    Marder VJ; Matchett MO; Sherry S
    Am J Med; 1971 Jul; 51(1):71-82. PubMed ID: 4998883
    [No Abstract]   [Full Text] [Related]  

  • 11. [Assay methods and significance of fibrin-fibrinogen degradation products in blood].
    Shinada S
    Nihon Ketsueki Gakkai Zasshi; 1972 Oct; 35(5):607-16. PubMed ID: 4677376
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrin-fibrinogin degradation products in cardiovascular surgery.
    Call FL; Schroeder ET; Parker FB; Davey FR
    Arch Surg; 1973 Dec; 107(6):834-7. PubMed ID: 4751825
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of in vivo produced fibrinogen-fibrin intermediates on viscosity of human blood.
    Blättler W; Straub PW; Peyer A
    Thromb Res; 1974 Jun; 4(6):787-801. PubMed ID: 4858453
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative activities of amino acid and polypeptide inhibitors on natural and synthetic substrates.
    Skoza L; Tse AO; Semar M; Johnson AJ
    Ann N Y Acad Sci; 1968 Jun; 146(2):659-72. PubMed ID: 4239440
    [No Abstract]   [Full Text] [Related]  

  • 15. [Detection of fibrinogen and fibrin degradation products (FDP) and its clinical significance].
    Fujimaki M; Ikematsu S; Takeuchi I
    Nihon Rinsho; 1973 Apr; 31(4):798-804. PubMed ID: 4580396
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunoephelometric determination of fibrinogen and its derivatives in plasma.
    Farrell GW; Wolf P
    J Immunol Methods; 1972 May; 1(3):217-29. PubMed ID: 4116307
    [No Abstract]   [Full Text] [Related]  

  • 17. The results of a comparison of the tanned red cell hemagglutination inhibition immuno-assay with an immunochemical method for the determination of splitproducts.
    Bouma BN
    Scand J Haematol Suppl; 1971; 13():111-4. PubMed ID: 4258197
    [No Abstract]   [Full Text] [Related]  

  • 18. Zinc inhibits FPA release and increases fibrin turbidity.
    Marx G; Hopmeier P
    Am J Hematol; 1986 Aug; 22(4):347-53. PubMed ID: 3728455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunological demonstration of fibrinogen-fibrin break-down products in serum and urine. Clinical significance].
    Gormsen J; Clausen NT
    Ugeskr Laeger; 1973 Aug; 135(32):1682-7. PubMed ID: 4589773
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of methods for the detection and quantitation of serum fibrin-fibrinogen degradation products.
    Erickson C; String T; Stewart D; Cohen RJ
    Am J Clin Pathol; 1972 Oct; 58(4):394-9. PubMed ID: 4674336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.